EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0Y3M: Prothena Corporation PLC

07 Nov 2025
LAST:

9.730

CHANGE:
 0.66		OPEN:
10.490		HIGH:
10.490		ASK:
0.000		VOLUME:
996
CHG(%):
6.35		PREV:
10.390		LOW:
9.730		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 2510.49010.4909.7309.730996
06 Nov 2510.27010.39610.27010.390478
05 Nov 2510.29010.29010.07010.276301
04 Nov 2510.34010.52010.19510.2201.8K
03 Nov 2511.00011.00010.70010.876348
31 Oct 2510.40010.72410.40010.540277
30 Oct 2510.71410.76010.35010.525325
29 Oct 2510.76010.76010.50010.620366
28 Oct 2510.73011.66810.70010.70015.9K
27 Oct 259.98010.3609.92010.320725

COMPANY PROFILE

Name:Prothena Corporation PLC
About:Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Address:77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60
Website:https://www.prothena.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:0.08 
Price to Sales:34.32 
Price to Book:1.81 
Profit Margin:0.92 
Operating Margin:-11.77 
Return on Assets:-0.30 
Return on Equity:-0.67 
EPS Ratio:1.34 
Revenue:10.34M 
EBITDA:8.14M 
Shares:39.86M 
Market Cap:387.87M 

TECHNICAL INDICATORS

MA5:10.305.8%
MA10:10.427.1%
MA20:10.295.7%
MA50:9.502.4%
MA100:8.3017.2%
MA200:9.423.3%
RSI14:40.06
WPR14:-100.00 
MTM14:-0.69
ROC14:-0.07 
ATR:0.45 
Week High:11.0013.1%
Week Low:9.730.0%
Month High:11.6719.9%
Month Low:9.633.3%
Year High:18.5690.8%
Year Low:4.34124.1%
Volatility:31.97